Invention Grant
- Patent Title: KCNQ potassium channel agonist, and preparation method therefor and use thereof
-
Application No.: US15870276Application Date: 2018-01-12
-
Publication No.: US10316008B2Publication Date: 2019-06-11
- Inventor: Fajun Nan , Min Li , Zhaobing Gao , Yangming Zhang , Haining Hu , Haiyan Xu , Huanan Liu , Xiaoping Pi
- Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
- Applicant Address: CN Shanghai
- Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
- Current Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
- Current Assignee Address: CN Shanghai
- Agency: Morris, Manning & Martin, LLP
- Agent Ping Wang
- Priority: CN201410175315 20140428
- Main IPC: C07D307/24
- IPC: C07D307/24 ; A61K31/167 ; A61K31/17 ; A61K31/27 ; A61K31/277 ; A61K31/341 ; C07C269/04 ; C07C269/06 ; C07C271/28 ; C07C273/18 ; C07C275/64 ; C07C231/02 ; C07C333/08 ; C07C233/62 ; C07C235/16 ; C07C235/74 ; C07C237/04 ; C07C237/22 ; C07C237/48
Abstract:
The present invention provides a compound represented by general formula I or a pharmaceutical acceptable salt thereof, the preparation method therefor and the use thereof in preparing a medicine for treating a neurological disease, such as epilepsy, convulsion, neuropathic pain, acute ischemic stroke, and a neurodegenerative disease. The compound according to present invention has a better absorption in brain tissue when compared with RTG. In addition, the compound provided by present invention has not only a greatly enhanced efficacy, but also a neurotoxicity greatly lower than that of RTG, and thus possesses a wider safety window.
Public/Granted literature
- US20180134677A1 NOVEL KCNQ POTASSIUM CHANNEL AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF Public/Granted day:2018-05-17
Information query
